Receptor bias: difference between revisions
Diff·revision 19 → 20·15:08, 27 Aug 2025
Difference between revision 19 and revision 20 of Receptor bias. 3 lines changed; the page grew by 477 bytes.
| Revision 19 — 19:02, 2 Aug 2025 DPP4_Dagmar (talk) state that the enzyme inhibitor class works by raising endogenous levels 4,000 bytes ±0 | Revision 20 — 15:08, 27 Aug 2025 AmylinAmos (talk) expand §Status of the idea 4,477 bytes +477 | ||
|---|---|---|---|
| 32 | The honest summary is that the phenomenon is established, its molecular basis is understood, and its clinical exploitation at this target has not been demonstrated.{{r|jones2018}} | 32 | The honest summary is that the phenomenon is established, its molecular basis is understood, and its clinical exploitation at this target has not been demonstrated.{{r|jones2018}} |
| 33 | 33 | ||
| + | 34 | For a reader encountering bias claims in promotional material, the useful questions are which pathways were compared, against which reference agonist, and whether any clinical endpoint was measured.{{r|drucker2018}} None of these is a property a certificate of analysis reports, and a bias claim is not a quality attribute.{{r|usp1503}} | |
| + | 35 | ||
| 34 | == References == | 36 | == References == |
| 35 | {{reflist}} | 37 | {{reflist}} |
| ⋮ | ⋮ | ||
| 37 | <ref name="kenakin2013">Kenakin T, Christopoulos A. "Signalling bias in new drug discovery: detection, quantification and therapeutic impact." ''Nature Reviews Drug Discovery'' 12(3):205–216 (2013). PMID 23411724.</ref> | 39 | <ref name="kenakin2013">Kenakin T, Christopoulos A. "Signalling bias in new drug discovery: detection, quantification and therapeutic impact." ''Nature Reviews Drug Discovery'' 12(3):205–216 (2013). PMID 23411724.</ref> |
| 38 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 40 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| + | 41 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 39 | 42 | ||
| 40 | == See also == | 43 | == See also == |